Objective
to compare the 18-month clinical outcomes of a thin-strut biodegradable polymer sirolimus-eluting cobalt chromium stent (ORSIRO) with a thick-strut biodegradable polymer biolimus-eluting stent (BioMatrix)
Study
open-label, multicentre, non-inferiority randomised trial (margin 1.5%)
Population
patients with chronic stable angina or AC syndromes
Endpoints
target lesion failure as composite of cardiac death, MI, ischaemia-driven target lesion revascularisation within 18 months
Conclusion
in all-comers treated with PCI ORSIRO stents were non-inferior to BioMatrix stents
Yoon et al. EuroIntervention. 2021;16:1404-12